Aviado · Research
Longevity Daily
Friday, June 12, 2026
Listen
Today's Brief
This edition leads with a genuinely historic milestone: the world's first human trial of partial epigenetic cellular reprogramming has officially begun, crossing a threshold the longevity field has been racing toward for decades. On the supplement front, a new study delivers an important warning — glucosamine, taken by millions for joint pain, is linked to a 25% higher risk of dementia progression in cognitively impaired adults. Metformin adds to its growing résumé with a 50% reduction in long COVID risk in a randomized trial, and a two-year vitamin K2 RCT shows real slowing of coronary artery calcification.
10 stories6 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Popular Joint Supplement Glucosamine Linked to 25% Higher Dementia Risk in At-Risk Adults
A new study finds that people with mild cognitive impairment who were taking glucosamine supplements were 25% more likely to progress to full dementia than non-users — and nearly 1 in 10 cognitively declining patients in the study cohort were using it. Researchers suggest glucosamine may cross the blood-brain barrier and alter glycosylation of brain proteins, potentially accelerating amyloid plaque and tau tangle formation. If you or someone you care for is experiencing early memory changes, this study is a strong reason to discuss glucosamine use with your physician before your next refill.
Read more →Creatine Supports More Than Muscles — Evidence Mounts for Cognitive Benefits in Aging Adults
Beyond its well-established role in muscle performance, creatine is gaining real traction as a brain supplement — studies show it can improve short-term memory and reasoning, with particular promise for older adults facing age-related cognitive decline. Experts note that creatine fuels neurons the same way it fuels muscle cells, which likely explains the cognitive lift observed in supplementation studies. It's widely considered safe at standard doses, making it one of the more accessible dual-purpose compounds in a longevity stack — though as always, consult your physician before adding anything new.
Read more →The Debate Is Settling: Adult Humans Do Grow New Brain Cells — And It Changes Dementia Prevention
A new perspective paper from University of Wisconsin-Madison researchers argues that decades of scientific dispute over adult hippocampal neurogenesis — whether the human brain can grow new neurons in its primary memory center — has tilted decisively toward 'yes.' This matters because the hippocampus is the region most devastated by Alzheimer's, and demonstrating that it retains stem cell capacity opens therapeutic windows for dementia prevention that current drugs don't touch. This is a perspective piece, not primary data, but it reflects a meaningful shift in neuroscience consensus that will shape the next generation of cognitive aging research.
Read more →Supplements & Compounds
Two Years of Vitamin K2 (MK-7) Significantly Slows Coronary Artery Calcification in 180-Person RCT
A randomized clinical trial of 180 adults published in JAMA Cardiology found that two years of menaquinone-7 (vitamin K2) supplementation significantly reduced coronary artery calcification progression compared to placebo. CAC score is one of the strongest independent predictors of heart attack risk, making this a clinically meaningful result for anyone using cardiovascular aging as a health metric. The study adds weight to the hypothesis that K2 redirects calcium away from arterial walls and into bones — building a solid evidentiary case for its place in a cardiovascular supplement protocol.
Read more →Research & Papers
World First: A Human Has Received an Epigenetic Cellular Reprogramming Therapy — The Longevity Clock Just Changed
For the first time in history, a patient has been injected with a therapy designed to epigenetically 'reset' aging cells — marking the start of what may be the most consequential clinical trial in longevity medicine to date. Life Biosciences' ER-100 uses partial Yamanaka factor reprogramming to restore younger epigenetic patterns in damaged retinal cells, with FDA clearance for its Phase 1 safety trial granted in January 2026. Earlier testing in mice and non-human primates showed promising regeneration of optic nerve tissue, providing the scientific basis for the human trial. This is a Phase 1 safety study only — efficacy data are years away — but the ethical and scientific threshold crossed here is real, and the longevity field will not look the same after it.
Read more →Metformin Cuts Long COVID Risk by 50% in Randomized ACTIV-6 Trial
In the ACTIV-6 randomized controlled trial, participants who received metformin during acute COVID-19 infection were 50% less likely to receive a clinical diagnosis of long COVID at six months compared to placebo. This is among the strongest RCT evidence yet that a pharmacological intervention can meaningfully prevent long COVID — a condition affecting tens of millions globally and linked to prolonged fatigue, cognitive dysfunction, and cardiovascular stress. For the longevity community already watching metformin's anti-aging research closely, this adds another compelling data point — though it's worth noting the drug was administered during acute infection, not as a standing preventive prescription.
Read more →Aviado Research: Latest In-Depth Longevity Analysis
Aviado Research's latest review synthesizes emerging findings across aging biology and longevity science, offering evidence-based commentary for health-conscious readers who want more than headlines. Read the full analysis for Aviado's perspective on what's actually worth your attention.
Read the full Aviado analysis →Lifestyle & Nutrition
Your VO2 Max at 34 Predicts Arterial Stiffness at 63 — Better Than Any Cholesterol Marker
A longitudinal cohort study finds that aerobic capacity measured at age 34 outperforms both conventional and advanced lipid markers — including apolipoprotein metrics — in predicting arterial stiffness nearly three decades later. Arterial stiffness at 63 is a key driver of stroke, heart failure, and cognitive decline, making early cardiorespiratory fitness one of the highest-leverage investments in long-term health. The message is direct: building VO2 max in your 30s and 40s appears to matter more for vascular aging than optimizing your lipid panel.
Read more →Flossing and Tongue Scraping Linked to Significantly Lower All-Cause Mortality in Large Longitudinal Study
A large longitudinal study finds that routine oral hygiene practices — specifically flossing and tongue scraping — are associated with meaningfully lower all-cause mortality in older adults. The likely mechanism: oral bacteria that accumulate without regular cleaning enter the bloodstream and drive systemic inflammation linked to cardiovascular disease, dementia, and metabolic dysfunction. It may be the most cost-effective longevity intervention available — zero risk, under two minutes daily, and essentially free.
Read more →Industry & Policy
Longevity Biotech Attracted $3.74 Billion in Q1 2026 — Up 56% Year-Over-Year
Longevity biotech companies raised $3.74 billion across 49 deals in Q1 2026 alone, a 56% increase over the same period last year, according to Longevity.Technology analysis of PitchBook data. The surge reflects accelerating conviction from major capital allocators — including billionaires and institutional funds — that aging biology is the next transformational medicine frontier. For readers tracking the field, this influx signals that therapies being explored in research labs today are moving toward clinical deployment faster than most previous timelines projected.
Read more →